Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155019 | 1.00 | AOC3 (0.53) | AOC3KDM4ESCN9ATRPA1CYP3A4 | |
| SCHEMBL16340559 | 1.00 | AOC3 (0.53) | AOC3KDM4ESCN9ATRPA1CYP3A4 | |
| SCHEMBL28920057 | 0.88 | AOC3 (0.44) | AOC3KDM4ESCN9AGABBR2GABBR1 | |
| SCHEMBL17438169 | 0.87 | TSHR (0.48) | AOC3KDM4ECYP3A4TSHR | |
| SCHEMBL28920019 | 0.86 | AOC3 (0.43) | AOC3KDM4ESCN9AGABBR2GABBR1 | |
| SCHEMBL9250397 | 0.81 | AOC3 (0.50) | AOC3KDM4ECYP3A4TSHRMEN1 | |
| SCHEMBL3183272 | 0.81 | AOC3 (0.50) | AOC3KDM4ECYP3A4TSHRMEN1 | |
| SCHEMBL9246291 | 0.81 | AOC3 (0.50) | AOC3KDM4ECYP3A4TSHRMEN1 | |
| SCHEMBL27650038 | 0.80 | AOC3 (0.53) | AOC3KDM4EGABBR2GABBR1HTT | |
| SCHEMBL13786104 | 0.79 | AOC3 (0.48) | AOC3KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20160097063-A1 | Production Of Enantiopure alpha-Hydroxy Carboxylic Acids From Alkenes By Cascade Biocatalysis | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-04-07 | — | — | US | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | AOC3 1464/4885KDM4E 40/4885SCN9A 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.